(Q45228821)

English

Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level

scientific article published on 16 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level (English)

1 reference

Europe PubMed Central

11 December 2017

0 references

quality of life

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

author name string

I Ertenli

1

1 reference

Europe PubMed Central

11 December 2017

S Ozer

2

1 reference

Europe PubMed Central

11 December 2017

S Kiraz

3

1 reference

Europe PubMed Central

11 December 2017

S B Apras

4

1 reference

Europe PubMed Central

11 December 2017

A Akdogan

5

1 reference

Europe PubMed Central

11 December 2017

O Karadag

6

1 reference

Europe PubMed Central

11 December 2017

M Calguneri

7

1 reference

Europe PubMed Central

11 December 2017

U Kalyoncu

8

1 reference

Europe PubMed Central

11 December 2017

publication date

16 November 2010

1 reference

Europe PubMed Central

11 December 2017

Rheumatology International

1 reference

Europe PubMed Central

11 December 2017

32

1 reference

Europe PubMed Central

11 December 2017

2

1 reference

Europe PubMed Central

11 December 2017

323-330

1 reference

Europe PubMed Central

11 December 2017

https://scigraph.springernature.com/pub.10.1007/s00296-010-1616-x

0 references

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Disease and psychological status in ankylosing spondylitis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Cytokines sing the blues: inflammation and the pathogenesis of depression

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Cytokines: abnormalities in major depression and implications for pharmacological treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Infliximab improves quality of life in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Increase in Interleukin-1β in Late-Life Depression

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1616-X

21 January 2018

Cytokine production and treatment response in major depressive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating depressed primary care patients improves their physical, mental, and social functioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of major depression on chronic medical illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mood disorders in the medically ill: scientific review and recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The status of health assessment 1994.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gender, depression, and ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21079965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-010-1616-X

1 reference

Europe PubMed Central

11 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45228821&oldid=2070707118"